ArticleNaunyn-Schmiedeberg's archives of pharmacology2018
Baicalin alleviates oxidative stress damage in trabecular meshwork cells in vitro.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Baicalin as a multifunctional flavone glycoside: pharmacological mechanisms, ADME profile, and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Interdisciplinarity traditional Chinese medicine microneedles in skin disease treatment: Recent advances and challenges.Bioactive materials · 2026Review
- Protective effect of baicalin on oxidative stress injury in retinal ganglion cells through the JAK/STAT signaling pathwayFrontiers in pharmacology · 2024Article
- Evaluation of Carbonic Anhydrase, Acetylcholinesterase, Butyrylcholinesterase, and α-Glycosidase Inhibition Effects and Antioxidant Activity of Baicalin Hydrate.Life (Basel, Switzerland) · 2023Article
- Chemical Characterization and Determination of the Antioxidant Properties of Phenolic Compounds in ThreeMolecules (Basel, Switzerland) · 2023Article
- Herbal and Natural Treatments for the Management of the Glaucoma: An Update.BioMed research international · 2023Review
- Scutellaria baicalensis and its constituents baicalin and baicalein as antidotes or protective agents against chemical toxicities: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Research progress on pharmacological effects and new dosage forms of baicalin.Veterinary medicine and science · 2022Review
- Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update.Nutrients · 2022Review
- Baicalin suppresses glaucoma pathogenesis by regulating the PI3K/AKT signaling in vitro and in vivo.Bioengineered · 2021Article
- Baicalin Alleviates LPS-Induced Oxidative Stress via NF-κB and Nrf2-HO1 Signaling Pathways in IPEC-J2 Cells.Frontiers in veterinary science · 2021Article
- Analysis and Construction of a Competitive Endogenous RNA Regulatory Network of Baicalin-Induced Apoptosis in Human Osteosarcoma Cells.BioMed research international · 2021Article
- Vitreous albumin redox state in open-angle glaucoma patients and controls: a pilot study.International ophthalmology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress and inflammation play a key role in pathophysiology of glaucoma. Baicalin is known as an anti-oxidative and anti-inflammatory substance, possessing the potential to treat glaucoma. This study was designed to assess the anti-oxidative and anti-inflammatory potentials in culture human trabecular meshwork (hTM) cells. Using hTM cells as the in vitro model, we investigated the effects of baicalin on oxidative stress-induced markers for hTM impairments. We pre-incubated hTM cells with baicalin before hydrogen peroxide stressing or pre- plus co-incubated with baicalin before and during stressing and monitored the cell death, production of intracellular reactive oxygen species (iROS) and inflammatory cytokines, accumulation of carbonylated proteins, and activity of senescence marker. Samples that received pre- plus co-treatment with 10 or 15 μM baicalin showed significantly increased cell survival and decreased iROS production. Further studies demonstrated that pre- plus co-treatment with 15 μM baicalin significantly inhibited proinflammatory factor IL-1α and ELAM-1 production, decreased activities of senescence marker SA-β-gal, and lowered carbonylated protein levels. In contrast, samples that received only pre-treatment did not show any of these protective effects. Baicalin can protect hTM cells against oxidative stress, shedding light on potential treatment for glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.